A phase 1b randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of the liver-selective TR-beta agonist VK2809 (MB07811) in hypercholesterolemic subjects.

Trial Profile

A phase 1b randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of the liver-selective TR-beta agonist VK2809 (MB07811) in hypercholesterolemic subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Metabasis Therapeutics
  • Most Recent Events

    • 16 Nov 2016 Results of effect of VK-2809 on lipoprotein-A and Apolipoprotein B presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 15 Nov 2016 According to Viking Therapeutics Media Release, results were presented in a poster presentation at the American Heart Association (AHA) Scientific Sessions 2016.
    • 15 Nov 2016 Results published in the Viking Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top